Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Slides:

Advertisements

Similar presentations

Atorvastatin in Type 2 diabetics on dialysis: 4D Study 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF;

Advertisements

P Sever (Co-chair), B Dahlöf (Co-chair), N Poulter (Secretary), H Wedel (Statistician), G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson,

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

Trial profile Fox K et al. Lancet 2008;372:

Cholesterol quintile (mg/dL)

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

Philip J. Barter, et al. Circulation 2011;124:

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

ASCOT and Steno-2: Aggressive risk reduction benefits two different patient populations *Composite of CV death, nonfatal MI or stroke, revascularization,

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

P Sever (Co-chair), B Dahlöf (Co-chair), N Poulter (Secretary), H Wedel (Statistician), G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson,

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Baseline characteristics of HPS participants by prior cerebrovascular disease.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

LEADER trial: Primary Outcome

Baseline Characteristics of the Patients Part I

The Anglo Scandinavian Cardiac Outcomes Trial

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

on behalf of the ASCOT Investigators *Imperial College London, UK

Baseline characteristics of patients

Robert W. Yeh et al. JACC 2017;70:

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

ASCOT-BPLA: Primary and secondary end points

Jun M, et al. Lancet 2010 Epub May 10

A: Kaplan-Meier estimate of time to first LLA

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Description of studies for pooled analyses

Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.

LDL Cholesterol.

Daan Kromhout, et al. NEJM epub August 29, 2010

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.

Baseline Characteristics According to Sex

Flow of Patients Through Trial

Study Participant Flow

Baseline Characteristics of the Study Participants

Baseline Characteristics of the Subjects*

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Baseline Characteristics of the Patients – Part I

Baseline characteristics of older women (NHS I), younger women (NHS II), and men (HPFS) with a history of hypertension according to thiazide use Eric N.

Baseline Characteristics by hs-CRP

Baseline plasma levels of cathepsin D (A), cathepsin L (B) and cystatin B (C) are increased in individuals who developed coronary events (CEs) during follow-up.

Brugts JJ, et al. BMJ 2009;338:b2376.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs polymorphism and the dietary intervention group after.

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Shown are cumulative incidence curves of TNNHS and DPT-1 participants who either had DPTRS values >7.00 (A) or dysglycemia (B). Shown are cumulative incidence.

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Baseline predictors for risk of cardiovascular events or all-cause mortality among immigrants with language barriers (N = 87,707). *Adjustment for all.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Kaplan-Meier curves of ventricular arrhythmia–related events (A), death from MI (B), or both end points combined (C). Kaplan-Meier curves of ventricular.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Presentation transcript:

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157

Baseline characteristics for patients with diabetes in ASCOT-LLA Part II P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157

Plasma lipid concentrations (mmol/ l) by visit and treatment (diabetic patients only) P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157

Cumulative incidence for total cardiovascular events and procedures among diabetic participants in ASCOT-LLA P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157

Effect of atorvastatin and placebo on cardiovascular (CV) and coronary end points by diabetic status in ASCOT-LLA P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157

HR by subgroups (diabetic patients only) for total cardiovascular events and procedures P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157

HR for end points included in total cardiovascular events and procedures (diabetic patients only) P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157